CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. (CBLL) has a notice filed under Rule 144 for the planned sale of its common stock by officer Scott E. Blumberg. The filing covers up to 1,521 shares of Ceribell common stock held at Fidelity Brokerage Services LLC, with an aggregate market value of $36,537.15 as of the notice date, to be sold on NASDAQ. The shares were acquired through restricted stock vesting on August 20, 2026. The notice states that the sale includes an amount necessary to cover a tax obligation arising from the settlement of a vested equity award distribution. The filing also lists several Ceribell stock sales by Blumberg over the prior three months.
Ceribell, Inc. (CBLL) received a notice under Rule 144 that officer David J. Foehr plans to sell 993 shares of Ceribell common stock through Fidelity Brokerage Services LLC on or after August 21, 2026, following restricted stock vesting. The sale includes shares to cover a tax obligation from settlement of a vested equity award distribution. In the prior three months, Foehr reported sales of 987 shares on May 21, 2026 for $17,761.95 and 862 shares on May 22, 2026 for $16,205.60.
Ceribell, Inc. (CBLL) has a notice of proposed sale of common stock under Rule 144 filed for the account of officer Raymond Woo. The securities are held at Fidelity Brokerage Services. The notice covers 1,979 shares of common stock that became deliverable through restricted stock vesting and are expected to be sold on or after 08/20/2026. A portion of the sale is described as covering a tax obligation arising from the settlement of a vested equity award distribution. The filing also reports that 1,966 shares of common stock were sold on 05/21/2026 during the prior three months.
Ceribell, Inc. (CBLL) is the issuer of common stock for which officer Joseph S. Manni has filed a notice of proposed sale under Rule 144. The notice covers 1,361 shares of common stock held at Fidelity Brokerage Services LLC with an indicated value of $32,693.67, tied to restricted stock vesting on August 20, 2026. A prior sale of 1,378 shares for $24,798.35 occurred on May 21, 2026, and the current sale includes shares to cover a tax obligation from the vested equity award distribution.
Ceribell, Inc. (CBLL) is the issuer for a planned resale of its common stock under Rule 144 by security holder Xingjuan Chao. The notice covers an intended sale of 6,068 shares of common stock held at Fidelity Brokerage Services LLC, with securities becoming sale-eligible on 08/21/2026. The shares to be sold arise from restricted stock vesting on 08/20/2026, and the sale includes an amount to cover a tax obligation from settlement of a vested equity award.
Over the prior three months, Xingjuan Chao has reported multiple sales of Ceribell common stock, including 6,030 shares on 05/21/2026, and several blocks of 39,000 shares on 06/08/2026, 07/07/2026, and 08/03/2026, plus smaller sales on 08/18/2026 and 08/19/2026.
Ceribell, Inc. (CBLL) reported insider transactions by Chief Financial Officer Scott Blumberg on August 18–19, 2026. Blumberg exercised stock options covering 34,502 shares of common stock at exercise prices of $4.70 and $9.41 per share, then sold 34,502 shares of common stock at prices around $25 per share, including a weighted average sale price of $25.03. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
Ceribell, Inc. (symbol: CBLL) is the issuer of record for a Form 4/A filing submitted to the SEC.
Ceribell, Inc. (CBLL) reported that President and CEO Chao Xingjuan sold a total of 33,614 shares of common stock in open-market transactions on August 18–19, 2026, at prices around $25 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan. Xingjuan also reported an indirect holding of 369,088 shares of common stock held by the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership except to the extent of her pecuniary interest. The August 19 sale price is disclosed as a weighted average with individual trade prices ranging from $25.00 to $25.30.
Ceribell, Inc. (CBLL) is the issuer for a planned resale of its common stock by officer Scott E. Blumberg under Rule 144. The notice covers up to 33,512 shares of common stock to be sold through Fidelity Brokerage Services LLC, following acquisition via a stock option exercise for cash. The filing also lists prior sales of smaller share amounts by Blumberg within the preceding three months.
Ceribell, Inc. (CBLL) is the issuer for a planned resale of its common stock under Rule 144 by security holder Xingjuan Chao, using Fidelity Brokerage Services LLC as broker. The notice covers a proposed sale of 31,415 shares of common stock, with an aggregate market value of $786,364.46, when 38,378,101 shares of this class were outstanding as of 08/19/2026.
The shares to be sold were acquired through a stock option exercise on 04/30/2018, for cash, from the issuer. The filing also lists several prior sales of Ceribell common stock by Xingjuan Chao during the past three months, reflecting ongoing liquidity activity by this holder.